The importance of releasing BIM for cell death activation is exemplified by the treatment of BCL-2High DLBCL with ABT-199 or the BCL-XL-selective inhibitor A-1155463 which results in ejection of BIM from these proteins but subsequent sequestration by MCL-1 [11]. Here, MCL1 is linked to diffuse large B-cell lymphoma.